Predict your next investment

Venture Capital
biomaticscapital.com

See what CB Insights has to offer

Investments

30

Portfolio Exits

6

Funds

2

About Biomatics Capital Partners

Biomatics Capital Partners is a for-profit venture firm that joins with leading innovators and entrepreneurs translating science and technology into the next generation of world-class healthcare companies. By integrating the best of science with sound investment practice, the Fund will create extraordinary financial value for investors and health outcomes for communities.

Biomatics Capital Partners Headquarter Location

719 2nd Avenue Suite 1402

Seattle, Washington, 98104,

United States

206-240-3943

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Biomatics Capital Partners

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Biomatics Capital Partners in 1 Expert Collection, including Pharma Startups.

P

Pharma Startups

5,090 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

Latest Biomatics Capital Partners News

Compass Therapeutics Appoints Julie Sunderland to Board of Directors

Aug 1, 2019

Julie is co-founder and managing partner of Biomatics Capital Partners. She served as interim CEO of biotechnology company eGenesis from December 2017 through January 2019. Prior to co-founding Biomatics in 2016, she was the director of program-related investments for the Bill & Melinda Gates Foundation, where she led the foundation’s $1.5 billion strategic investment pool and funded over 50 investments. She also chaired the Bill & Melinda Gates Foundations’ investment committee. Earlier in her career Julie advised foundations, development finance institutions and governments on venture capital, SME financing and technical assistance programs. Julie holds a B.A. from Harvard University, an MBA from Wharton Business School and an M.A. from Johns Hopkins School of Advanced International Studies. “Compass’ research is defining a new era for antibody therapeutics, bringing hope to patients worldwide, and I’m proud to help advance this important cause,” said Julie. “I look forward to working with my fellow Board members to push these novel therapies forward.” Julie will succeed Errik Anderson, MBA, co-founder of Compass Therapeutics and chief executive officer of Ulysses Diversified Holdings, as a member of the Board. Errik co-founded Compass in 2014 and has been with the company in both operational and Board roles since that time. “As Compass has grown from an early-stage drug discovery company to a clinical-stage company with a robust and promising pipeline, Errik has been a torchbearer for our work to transform care for patients with cancer or autoimmune diseases. We are grateful for his service over the years,” said Thomas Schuetz, M.D., Ph.D., co-founder and chief executive officer of Compass Therapeutics. “Errik has been an important partner to Biomatics in the antibody therapeutics space and first introduced us to the Compass team and story. As Errik takes on a new CEO role, I am excited to be succeeding him on the Compass Board to support the company as it continues to progress its robust pipeline of antibody therapeutics,” said Julie Sunderland. About Compass Therapeutics Compass Therapeutics is a clinical-stage biotechnology company targeting the human immune synapse with a new generation of monoclonal and multispecific antibody therapeutics. Compass has broadly drugged the immune system by generating epitopically diverse antibody panels to more than 40 targets across all immune cell types and is leveraging its proprietary StitchMabsTM and common light-chain based multispecific platforms to empirically identify combinations and multispecifics with optimized activity. The company’s lead product candidate, CTX-471, is a fully human agonistic antibody of CD137, which is in a Phase 1 study in patients with inadequate responses to PD-1/PD-L1 checkpoint inhibitors. Compass is also progressing several preclinical assets including a novel class of NK cell engaging bispecifics targeting NKp30 and multiple bispecific checkpoint programs. The company’s offices and labs are based in Kendall Square in Cambridge, Mass. View source version on businesswire.com: https://www.businesswire.com/news/home/20190801005162/en/ Lisa Raffensperger

Biomatics Capital Partners Investments

30 Investments

Biomatics Capital Partners has made 30 investments. Their latest investment was in Encodia as part of their Series C on January 1, 2021.

CBI Logo

Biomatics Capital Partners Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

1/27/2021

Series C

Encodia

$75M

Yes

Alexandria Venture Investments, ARCH Venture Partners, Decheng Capital, Deerfield Management, Google Ventures, Nan Fung Life Sciences, Northpond Ventures, and Tao Capital Partners

2

1/19/2021

Series B

Verve Therapeutics

$94M

No

Casdin Capital, Cormorant Asset Management, Google Ventures, Janus Henderson Investors, Logos Capital, Novo Holdings, RA Capital Management, Redmile Group, Rock Springs Capital, Surveyor Capital, Undisclosed Investors, and Wellington Management

3

1/19/2021

Series D

Aledade

$100M

No

Institutional Venture Partners, Meritech Capital Partners, OMERS Private Equity, Tiger Global Management, and Venrock

4

8/24/2020

Seed VC - III

Subscribe to see more

$99M

Subscribe to see more

10

8/5/2020

Unattributed VC

Subscribe to see more

$99M

Subscribe to see more

10

Date

1/27/2021

1/19/2021

1/19/2021

8/24/2020

8/5/2020

Round

Series C

Series B

Series D

Seed VC - III

Unattributed VC

Company

Encodia

Verve Therapeutics

Aledade

Subscribe to see more

Subscribe to see more

Amount

$75M

$94M

$100M

$99M

$99M

New?

Yes

No

No

Subscribe to see more

Subscribe to see more

Co-Investors

Alexandria Venture Investments, ARCH Venture Partners, Decheng Capital, Deerfield Management, Google Ventures, Nan Fung Life Sciences, Northpond Ventures, and Tao Capital Partners

Casdin Capital, Cormorant Asset Management, Google Ventures, Janus Henderson Investors, Logos Capital, Novo Holdings, RA Capital Management, Redmile Group, Rock Springs Capital, Surveyor Capital, Undisclosed Investors, and Wellington Management

Institutional Venture Partners, Meritech Capital Partners, OMERS Private Equity, Tiger Global Management, and Venrock

Sources

2

3

4

10

10

Biomatics Capital Partners Portfolio Exits

6 Portfolio Exits

Biomatics Capital Partners has 6 portfolio exits. Their latest portfolio exit was OmniOme on July 20, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

7/20/2021

Acquired

$991

7

00/00/0000

Subscribe to see more

Subscribe to see more

$991

Subscribe to see more

10

00/00/0000

Subscribe to see more

Subscribe to see more

$991

Subscribe to see more

10

00/00/0000

Subscribe to see more

Subscribe to see more

$991

Subscribe to see more

10

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

Date

7/20/2021

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Exit

Acquired

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$991

$991

$991

$991

Acquirer

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

7

10

10

10

10

Biomatics Capital Partners Fund History

2 Fund Histories

Biomatics Capital Partners has 2 funds, including Biomatics Capital Partners II.

Closing Date

Fund

Fund Type

Status

Amount

Sources

11/8/2018

Biomatics Capital Partners II

Multi-Stage Venture Capital

$300M

4

3/15/2017

Biomatics Capital Partners I

Subscribe to see more

$99M

10

Closing Date

11/8/2018

3/15/2017

Fund

Biomatics Capital Partners II

Biomatics Capital Partners I

Fund Type

Multi-Stage Venture Capital

Subscribe to see more

Status

Amount

$300M

$99M

Sources

4

10

Biomatics Capital Partners Team

1 Team Member

Biomatics Capital Partners has 1 team member, including undefined undefined, undefined.

Name

Work History

Title

Status

Boris Nikolic

Founder

Current

Name

Boris Nikolic

Work History

Title

Founder

Status

Current

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.